<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059136</url>
  </required_header>
  <id_info>
    <org_study_id>P071216</org_study_id>
    <nct_id>NCT01059136</nct_id>
  </id_info>
  <brief_title>Aldosterone Blockade Early After Acute Myocardial Infarction</brief_title>
  <acronym>ALBATROSS</acronym>
  <official_title>Aldosterone Lethal Effects Blocked in AMI Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-up: THE ALBATROSS TRIAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis : An early blockade of aldosterone receptors initiated at the first medical&#xD;
      contact after acute myocardial infarction may reduce major cardiovascular events within 6&#xD;
      months after the occurrence of the myocardial infarction.&#xD;
&#xD;
      Primary efficacy criterion : The 6 month rate of the composite of death, resuscitated cardiac&#xD;
      arrest, potentially lethal ventricular arrhythmia, indication for implantation of an&#xD;
      implantable cardioversion device, occurrence or aggravation of heart failure.&#xD;
&#xD;
      Primary objective: To demonstrate the superiority of aldosterone blockade initiated as soon&#xD;
      as possible within 72 hours after the onset of acute myocardial infarction on top of standard&#xD;
      therapy, compared to standard therapy alone, with or without reperfusion therapy.&#xD;
&#xD;
      Study design : Prospective, multi-centre randomised, open labeled with 2 parallel study arms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rational :The blockade of the renin-angiotensin-aldosterone (RAA) pathway by angiotensin&#xD;
      conversion enzyme inhibitors (ACEI) is one corner stone in the management of heart failure as&#xD;
      well as the management of ischemic heart disease, especially after acute myocardial&#xD;
      infarctionHigh plasma aldosterone levels have been associated with both direct and indirect&#xD;
      toxic effects on myocardium. ACEIs are associated with partial and temporary reduction of&#xD;
      plasma aldosterone levels.The RALES randomized controlled trial has shown a reduction of&#xD;
      mortality associated with the use of the selective aldosterone receptor blocker&#xD;
      spironolactone, on top of standard therapy including ACEIs in the setting of NYHA 3-4 chronic&#xD;
      heart failure. The EPHESUS randomized controlled trial has shown a reduction of mortality&#xD;
      associated with the use of another selective aldosterone receptor blocker Eplerenone,&#xD;
      initiated 3 to 14 days after acute myocardial infarction complicated by clinical heart&#xD;
      failure and left ventricular ejection fraction &lt; 40%.Both previous studies have also reported&#xD;
      a rapid reduction of global and arrhythmia-related mortality, within 30 days after the&#xD;
      initiation of the medication.Such benefit has been reported after delayed initiation of&#xD;
      aldosterone blocked, while aldosterone is at its highest level at presentation after acute&#xD;
      myocardial infarction, with a rapid decrease within days after admission. Furthermore high&#xD;
      aldosterone levels on admission are associated with adverse outcome independent of heart&#xD;
      failure.&#xD;
&#xD;
      The ALBATROSS trial :Hypothesis: An early blockade of aldosterone receptors initiated at the&#xD;
      first medical contact after acute myocardial infarction may reduce major cardiovascular&#xD;
      events within 6 months after the occurrence of the myocardial infarction.&#xD;
&#xD;
      Primary objective: To demonstrate the superiority of aldosterone blockade initiated as soon&#xD;
      as possible within 72 hours after the onset of acute myocardial infarction on top of standard&#xD;
      therapy, compared to standard therapy alone, with or without reperfusion therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The 6 month rate of the composite of death, resuscitated cardiac arrest, potentially lethal ventricular arrhythmia, indication for implantable cardioversion device, occurrence or aggravation of heart failure.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any of the criteria of the primary endpoint</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>primary endpoint+ myocardial infarction+stroke cardiovascular death</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death + resuscitated cardiac arrest</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death+resuscitated cardiac arrest+ventricular arrhythmia+indication for implantable defibrillator device</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death+heart failure</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute renal failure</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>primary endpoint</measure>
    <time_frame>hospital discharge and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of hyperkaliemia (&gt; 5.5 mmol.l-1)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1603</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1:Spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aldosterone blockade on top of standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2:Standard therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>Unique 200mg IV dose of Potassium Canrenoate followed by 25 mg daily oral dose of Spironolactone for 6 months</description>
    <arm_group_label>1:Spironolactone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 ans&#xD;
&#xD;
          2. Ischemic symptom of ≥ 20 minutes&#xD;
&#xD;
          3. Randomization within 72 hours after symptom onset&#xD;
&#xD;
          4. Electrocardiogram or biological evidence of myocardial infarction:&#xD;
&#xD;
               -  ST segment elevation ≥ 2 mm in ≥ 2 adjacent precordial derivations&#xD;
&#xD;
               -  ST segment elevation ≥ 1 mm in ≥ 2 adjacent peripheral derivations&#xD;
&#xD;
               -  New left bundle branch block&#xD;
&#xD;
               -  New significant Q wave in ≥ 2 adjacent peripheral derivations&#xD;
&#xD;
               -  Troponin levels ≥3 times upper local limit of normal values and Thrombolysis In&#xD;
                  Myocardial Infarction (TIMI) non-ST elevation myocardial infarction risk score ≥&#xD;
                  3.&#xD;
&#xD;
          5. Patients with health insurance&#xD;
&#xD;
          6. Written informed consent obtained from:&#xD;
&#xD;
               1. - the patient&#xD;
&#xD;
               2. -A member of the family or the person of confidence if the patient is unable to&#xD;
                  provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication or known intolerance to study drugs&#xD;
&#xD;
          2. Patients already treated by aldosterone blockers for diseases other than systemic&#xD;
             hypertension (e.g. primary hyperaldosteronism)&#xD;
&#xD;
          3. Hyperkaliemia &gt;5.5 mmol/l at the time of randomization&#xD;
&#xD;
          4. Renal function impairment :Plasma creatinin level &gt; 220 µmol/l and/or Creatinin&#xD;
             clearance 30 ml/min&#xD;
&#xD;
          5. Severe liver deficiency (Child-Pugh Class 3)&#xD;
&#xD;
          6. Pregnant or breast feeding women, or women desiring pregnancy within 6 months after&#xD;
             randomization&#xD;
&#xD;
          7. Patients already included in another biomedical intervention trial&#xD;
&#xD;
          8. Life expectancy &lt; 1 year&#xD;
&#xD;
          9. Cardiac arrest lasting (ECM) &gt;10 minutes prior to randomization&#xD;
&#xD;
         10. Patient unable or unwilling to comply with the treatment or the follow-up visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farzin BEYGUI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital PITIE-SALPETRIERE - Institut de Cardiologie</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2010</study_first_posted>
  <last_update_submitted>June 10, 2015</last_update_submitted>
  <last_update_submitted_qc>June 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Outcome</keyword>
  <keyword>Aldosterone</keyword>
  <keyword>Spironolactone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

